Science- and risk-based method development across analytical, cleaning, microbiological and manufacturing process disciplines — designed for regulatory robustness, operational reliability and long-term lifecycle management under ICH Q14, Q2(R2), FDA 21 CFR Part 211 and EU GMP.
Pharmaceutical and regulated manufacturers depend on their analytical, cleaning and process methods to release product, demonstrate process control and satisfy regulatory scrutiny. Yet methods are frequently developed reactively — optimised for initial approval rather than long-term operational robustness — and the consequences emerge at the worst possible moments: OOS results, failed batch releases, regulatory findings and costly revalidation exercises.
The 2024 adoption of ICH Q14 — alongside the revised ICH Q2(R2) — formalises what leading manufacturers have long recognised: method development is not a one-time event. It is the foundation of the analytical lifecycle. Methods must be designed with a defined Analytical Target Profile (ATP), developed within a Method Operable Design Region (MODR), and built to remain fit for purpose through post-approval change management without unnecessary revalidation burden.
Optimal brings an asset management perspective to method development: treating every method as a critical analytical asset whose reliability, fitness for purpose and lifecycle cost must be actively managed. The result is methods that pass regulatory review, perform consistently in production and transfer cleanly across sites and instruments.
Optimal delivers method development across the full range of disciplines required in regulated pharmaceutical, chemical and biotech manufacturing environments.
ICH Q14 (effective June 2024) establishes the analytical procedure lifecycle as the governing framework for method development. Optimal structures every engagement around this lifecycle, creating methods that are not just initially valid but operationally durable.
Every method Optimal develops is aligned to the regulatory frameworks applicable to your market — from initial development through to post-approval lifecycle management.
Optimal's method development programmes are structured around your regulatory context, product type and operational environment — whether you are developing methods for a new product, addressing regulatory findings, preparing for site transfer or planning a post-approval variation. Contact us to discuss scope and approach.
Request a scoping call